Literature DB >> 18329480

Mediastinoscopy might not be necessary in patients with non-small cell lung cancer with mediastinal lymph nodes having a maximum standardized uptake value of less than 5.3.

Benjamin Enoch Lee1, Jonathon Redwine, Cameron Foster, Elma Abella, Teri Lown, Derick Lau, David Follette.   

Abstract

OBJECTIVE: Accurate pretreatment staging in non-small cell lung cancer remains tantamount in formulating an appropriate treatment plan. The maximum standardized uptake value obtained with integrated fluorodeoxyglucose-positron emission tomography/computed tomography has been proposed to be a predictor of malignancy in mediastinal lymph nodes. A recent study has also suggested that accuracy of integrated fluorodeoxyglucose-positron emission tomography/computed tomography might be improved by increasing the maximum standardized uptake value used for calling a lymph node positive from 2.5 to 5.3. We tested the hypotheses that the maximum standardized uptake value is a predictor of individual lymph node metastasis in non-small cell lung cancer and that pathologic staging with mediastinoscopy might not be necessary in patients with a maximum standardized uptake value of less than 5.3 in their mediastinal lymph nodes.
METHODS: This is a retrospective review of 765 lymph nodes sampled from 110 patients in a single institution with biopsy-proved non-small cell lung cancer. All patients underwent integrated fluorodeoxyglucose-positron emission tomography/computed tomography before biopsy or resection of their mediastinal lymph nodes. Surgical staging was the reference standard. All N2 lymph nodes were individually assessed according to station. Data were analyzed by using the Pearson chi(2) test.
RESULTS: Twenty-one (19%) of 110 patients had N2 disease, and a total of 765 N2 lymph nodes were pathologically examined. The mean and median maximum standardized uptake values for N2 nodes with metastatic disease were 9.2 (95% confidence interval, 7.0-11.4) and 7.2 (range, 2.2-25.8), respectively. For benign N2 nodes, the mean and median maximum standardized uptake values were 1.5 (95% confidence interval, 1.4-1.6) and 1.0 (range, 1.0-9.6), respectively (P < .05). When integrated fluorodeoxyglucose-positron emission tomographic/computed tomographic scans were reinterpreted by using a maximum standardized uptake value of 5.3 as a cutoff for malignancy, sensitivity decreased from 93% to 81% (P = .15), specificity increased from 86% to 98% (P < .01), positive predictive value increased from 22% to 64% (P < .01), negative predictive value was unchanged at 99%, and overall accuracy of integrated positron emission tomography/computed tomography increased from 87% to 97% (P < .01).
CONCLUSIONS: The maximum standardized uptake value is a predictor of individual lymph node metastasis in non-small cell lung cancer. Accuracy of integrated positron emission tomography/computed tomography is significantly improved by using a maximum standardized uptake value of 5.3 to assign malignancy, thereby dramatically decreasing the number of false-positive results. More importantly, these results suggest that some patients with non-small cell lung cancer with a maximum standardized uptake value less than 5.3 in their N2 lymph nodes might be able to forego mediastinoscopy and proceed directly to thoracotomy. This represents a significant change in the current management of standardized uptake value-positive mediastinal lymph nodes in non-small cell lung cancer.

Entities:  

Mesh:

Year:  2008        PMID: 18329480     DOI: 10.1016/j.jtcvs.2007.09.029

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  9 in total

1.  Overcoming the hurdles of using PET/CT for target volume delineation in curative intent radiotherapy of non-small cell lung cancer.

Authors:  Leila Tchelebi; Hani Ashamalla
Journal:  Ann Transl Med       Date:  2015-08

2.  PET-CT in the staging and treatment of non-small-cell lung cancer.

Authors:  Patricia Ibeas; Blanca Cantos; José Manuel Gasent; Begoña Rodríguez; Mariano Provencio
Journal:  Clin Transl Oncol       Date:  2011-06       Impact factor: 3.405

3.  The role of mediastinoscopy for diagnosis of isolated mediastinal lymphadenopathy.

Authors:  Zubin M Nalladaru; Andre Wessels
Journal:  Indian J Surg       Date:  2011-04-30       Impact factor: 0.656

4.  Validating guideline concordant care in lung cancer also validates good surgical judgement and skill.

Authors:  Megan K Loo; Anthony W Kim
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

5.  Evaluation of mediastinal lymph nodes using F-FDG PET-CT scan and its histopathologic correlation.

Authors:  Arvind Kumar; Roman Dutta; Umashankkar Kannan; Rakesh Kumar; Gopi Chand Khilnani; Siddhartha Datta Gupta
Journal:  Ann Thorac Med       Date:  2011-01       Impact factor: 2.219

6.  FDG-PET parameters predicting mediastinal malignancy in lung cancer.

Authors:  M Serra Fortuny; M Gallego; Ll Berna; C Montón; L Vigil; M J Masdeu; A Fernández-Villar; M I Botana; R Cordovilla; R García-Luján; E Cases; E Monsó
Journal:  BMC Pulm Med       Date:  2016-12-08       Impact factor: 3.317

7.  Utility of EBUS-TBNA in PET-positive mediastinal lymph nodes in subjects with extra-thoracic malignancy.

Authors:  Ravindra M Mehta; Pavankumar Biraris; Shekhar Patil; Abhinav Singla; Kumar Kallur; Stefano Gasparini
Journal:  PLoS One       Date:  2019-03-11       Impact factor: 3.240

8.  Is Performance of Fluorine-18-fluorodeoxyglucose Positron Emission Tomography/Computed tomography (CT) or Contrast-enhanced CT Efficient Enough to Guide the Hilar Lymph Node Staging for Patients with Esophageal Squamous Cell Carcinoma?

Authors:  Li Chu; Shuai Liu; Tiantian Guo; Liqing Zou; Bin Li; Jianjiao Ni; Xi Yang; Xiao Chu; Fei Liang; Yida Li; Yuyun Sun; Qiao Li; Fang Yin; Guodong Li; Zhengfei Zhu
Journal:  Front Oncol       Date:  2022-02-25       Impact factor: 6.244

Review 9.  Positron Emission Tomography (PET) radiotracers in oncology--utility of 18F-Fluoro-deoxy-glucose (FDG)-PET in the management of patients with non-small-cell lung cancer (NSCLC).

Authors:  Evelina Miele; Gian Paolo Spinelli; Federica Tomao; Angelo Zullo; Filippo De Marinis; Giulia Pasciuti; Luigi Rossi; Federica Zoratto; Silverio Tomao
Journal:  J Exp Clin Cancer Res       Date:  2008-10-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.